REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
Deepbridge is delighted to announce that Dr Savvas Neophytou, Partner & Head of Life Sciences - Deepbridge Capital was awarded winner in the prestigious and fiercely contested Most Valuable Player category, at the seventh annual Growth Investor Awards, organised by Intelligent Partnership.
Deepbridge is delighted to announce that we were recognised as winners in the coveted Industry Game Changer category, at the seventh annual Growth Investor Awards, organised by Intelligent Partnership.
Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has secured £1.5 million in an Enterprise Investment Scheme (EIS) funding round ahead of a series A round next year.
VoxSmart Ltd, which is part of Deepbridge Technology Growth EIS portfolio, has recently cemented its Asia-Pacific (APAC) presence with the opening of a brand-new office in Queenstown, New Zealand, further building on it's global growth over the previous year.
Deepbridge are pleased to announce that we have sponsored the Hardman & Co’s TES White Paper, which investigates the effect of adding venture capital to equity/bond portfolios for investors. The paper also shows that venture capital makes a compelling addition, significantly improving investors’ risk/return profiles.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]
